There are 2789 resources available
1548P - A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
Presenter: Mrinal Gounder
Session: ePoster Display
1549P - Pazopanib exposure in advanced soft tissue and bone sarcoma: A pharmacokinetic/pharmacodynamic analysis
Presenter: Marie-Sophie Minot
Session: ePoster Display
1550P - A post hoc analysis of the EPAZ trial: The prognostic role of geriatric variables in elderly soft tissue sarcoma (STS) patients
Presenter: Rainer Hamacher
Session: ePoster Display
1551P - Efficacy of early phase trials for soft-tissue sarcoma patients: The Centre Léon Bérard and Gustave Roussy experience
Presenter: Elise Nassif
Session: ePoster Display
1552P - Magnitude of clinical benefit of cancer drugs used in advanced soft tissue sarcomas and GIST
Presenter: Raul Teres Lleida
Session: ePoster Display
1553TiP - A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma
Presenter: Christoph Schliemann
Session: ePoster Display
1555TiP - A phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS): The PULSAR trial
Presenter: Alice Indini
Session: ePoster Display
1568P - Clinical and laboratory outcomes of solid cancer patients reinfected with SARS-CoV-2
Presenter: Ozan Yazıcı
Session: ePoster Display
1569P - A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 infection optionally treated with granulocyte colony-stimulating factor (G-CSF): A comparative analysis
Presenter: Maria Sereno Moyano
Session: ePoster Display